INTRODUCTION
U BIQUITIN IS A HIGHLY CONSERVED 76-RESIDUE PROTEIN that regulates the function, distribution, and degradation of target proteins. It is added to proteins through isopeptide conjugation by the sequential actions of 3 enzymes, E1, E2, and E3. E3s can be characterized as containing HECT domain or RING finger (RF) and related domains (U-box and PHD domain) based on their structure. 1 They are responsible for recognizing and interacting with target proteins and catalyzing the final ligation of ubiquitin to a target protein. MDM2 (mouse double minute 2) and its human homolog Hdm2 are RF E3s whose predominant cellular function is the regulation of p53 activity. In addition, MDM2 has been shown to self-ubiquitinate and is known to interact with proteins involved in cell cycle regulation and apoptosis (for a review, see Zhang and Zhang 2 ). MDM2 ubiquitinates p53, targeting it for proteasomal degradation. Overexpression of MDM2 may facilitate cell transformation by preventing p53 increase in response to oncogenic stimuli. As many as 20% of soft tissue tumors and 16% of osteosarcomas exhibit MDM2 amplification, 3 leading to decreased p53 levels and inhibition of a major apoptotic pathway. Identification of specific MDM2 inhibitors may therefore provide potential therapeutic agents for the treatment of these cancers (Fig. 1) .
In an analysis of the 79 new chemical entities approved for cancer therapy by the Food and Drug Administration (FDA) between 1981 and 2002, 65 originated from small organic molecules, and 48 (64%) of those were classified as natural products or natural product derivatives. 4 Given this successful history, the practicality and importance of continuing to screen natural product extracts for anticancer activity is clear. Natural product extracts do, however, contain many "nuisance compounds" such as tannins, sulfated polysaccharides, and inherently fluorescent molecules that can generate false-positive results in many high-throughput screening (HTS) platforms. [5] [6] [7] These attributes have made screening natural product extracts more difficult in many modern HTS platforms. 8 Electrochemiluminescence (ECL) has specific attributes that may make it ideal for assaying natural product extracts. ECL is an extremely sensitive detection platform that generates photons (by Ruthenium (II) tris-2,2′-bipyridine [TAG]) emitted at a longer wavelength (~620 nm) than most of the fluorescent compounds present in natural product extracts. ECL has also been used successfully in a wide variety of crude biological samples, including serum, plasma, and tumor/tissue homogenates. 9 Here we describe the utility of ECL in a high-throughput screen of natural product extracts for inhibitors of MDM2 ubiquitin ligase activity.
METHODS

Reagents
Calpain Inhibitor I (ALLN) was purchased from Calibiochem (La Jolla, CA). Adriamycin and anti-β-actin antibody were purchased from Sigma (St. Louis, MO). Anti-MDM2 antibody (Ab-1 and Ab-2) were purchased from Oncogene (Boston, MA). Anti-p53 monoclonal antibody DO-1 and anti-poly (ADP-ribose) polymerase (anti-PARP) polycolonal antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Extract preparation
Both natural product extracts and pure natural products were obtained from the Natural Product Extract Repository of the Developmental Therapeutics Program of the U.S. National Cancer Institute. Plant materials were extracted in the Natural Products Extraction Laboratory with a 1:1 mixture of dichloromethane and MeOH followed by 100% MeOH and then with water. This order was reversed for marine organisms, and all extracts were lyophilized and stored at -20 °C. Prior to testing, plates containing 50 μg of extract per well were reconstituted with 50 μL of 100% DMSO (organic) and 50 μL of 50% DMSO-water (aqueous), and 5 μL of a 1-mM solution of pure natural products was diluted to 263 μM with 100% DMSO.
Inhibition of MDM2 auto-ubiquitination
Cell lysate containing a glutathione-S-transferase (GST)-MDM2 fusion protein was prebound to glutathione-coated 384-well plates for 1 h. Cell lysates containing rabbit E1 (Meso Scale Discovery, Gaithersburg, MD) and E2 (UbcH5B 10 ; Meso Scale Discovery) were incubated for 30 min in reaction buffer (phosphate-buffered saline [PBS], adenosine triphosphate [ATP], dithiothreitol [DTT], and Ub) to precharge the E2 system. Samples and E1/E2 precharged mixture were added to MDM2 simultaneously and allowed to react for 30 min at room temperature (RT; positive control = DMSO, negative control = EDTA). The ubiquitination reaction was stopped by washing the plate with PBS, then TAG-labeled antibody in read buffer (TPA, surfactant, Tris) was added to the plate and incubated for 1 h at RT. Plates were read using a MesoScale Discovery Sector Imager 6000. Data from each plate were normalized to 100% inhibition (EDTA control) and 0% inhibition (DMSO control). Z′ factors 11 for each plate were calculated, and plates with values less than 0.5 were retested. Hits were defined as those extracts with percentage inhibition greater than 3 standard deviations higher than average for their source (plant, marine, microbial, or algae) and type (aqueous or organic). Additional E3 assays were performed as above except cell lysates containing GST-MuRF1, GST-XIAP, or GST-Nedd4 were bound to the plate.
Cell growth
Retinal pigment epithelium (RPE) and RPE-E1A 12 cells were grown in 1:1 DME/F12 media (HyClone, UT) supplemented with 10% fetal bovine serum and 0.3% sodium bicarbonate (Invitrogen, CA). p53/MDM2 null mouse embryonic fibroblasts (MEFs), U20S, C8, and A9 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum. All media were supplemented with 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2.5 mM L-glutamine.
Plasmid
Plasmids encoding the MDM2 and p53 have been described previously. 13, 14 Multiplex analysis of apoptotic biomarkers RPE or RPE-E1A cells were seeded into 96-well plates at 34,000 cells per well and allowed to attach overnight. Samples were added to cell media for 6 to 7 h before cell lysis. Cells were lysed in lysis buffer (150 mM NaCl, 20 mM Tris [pH 7.5], 1 mM EDTA, 1 mM EGTA, 1% Triton X-100; per 10 mL lysis buffer, 1 protease inhibitor tablet [Roche, Basel, Switzerland], 100 μL phosphatase inhibitor 1 [Sigma P-2850], 100 μL phosphatase inhibitor 2 [Sigma P-5726], and 100 μL 1M NaF) for 20 min on ice, and the total cell lysate was transferred to and incubated on a 96-well 4-spot plate with capture antibodies for total p53, pp53, cleaved PARP, and cleaved caspase 3 overnight at 4 °C. The cell lysate was then washed from the plate; detection solution, containing 10 nM each anti-pp53 or anticleaved PARP Ru-tagged antibodies, 5 nM anti-p53, and 0.5 nM anticleaved caspase 3 Ru-tagged antibodies in 1% bovine serum albumin (BSA) and 1% blocking solution (MesoScale Discovery) in Tris wash buffer, was added to the plate for 1 h before washing and adding read buffer.
Western blot
Cells were lysed with radio-immunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 1 μg/mL aprotinin, 100 μg/mL phenylmethylsulfonyl fluoride [PMSF], and 5 μg/mL leupeptin) and centrifuged at 12,000 rpm for 20 min at 4 °C. Supernatants were mixed with 4× SDS-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer (200 mM Tris [pH 6.8], 40% glycerol, 8% SDS, 400 mM DTT, 0.2% bromophenol blue) and heated at 100 °C for 3 min. Then, 8% or 10% Tris-Glycine gels were used to resolve the proteins. The gels were then transferred to the polyvinylidene fluoride (PVDF) membrane. Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline Tween-20 (TBST; 50 mM Tris [pH 8.0], 150 mM NaCl, 0.05% Tween-20), washed in TBST, and then incubated with specific antibody for 2 h. The membranes were again washed, incubated with horseradish peroxidase (HRP)-labeled antimouse or antirabbit antibodies for 30 min, and visualized.
p53 Signal transduction
U20S-pG13 cells 15 were incubated with sempervirine for 20 h. The cells were then washed and lysed with reporter lysis buffer (Promega, Madison, WI). The resultant lysates were centrifuged at 12,000 rpm for 20 min. Luciferase activity in the supernatant was determined according to the manufacturer's instructions (Promega).
RESULTS
Bioassay development
An electrochemiluminescent assay for the detection of selfubiquitinated E3 ligases was developed. Assay components include E1, E2 (UbcH5B), E3, ubiquitin, ATP, DTT, and a TAGlabeled anti-polyubiquitin antibody. The final product of the ligase reaction was a polyubiquitinated E3 that was visualized by CCD camera with the photon intensity digitized to provide a "heat map" of enzyme activity (Fig. 2) . Initial optimization was performed for MDM2, and conditions were modified for the additional E3 ligases Nedd4, MuRF1, and XIAP. The assay was optimized for E3 inhibition by maintaining reaction times within the linear range of E3 kinetics, ensuring that E3 was the limiting reagent, and precharging E2 with ubiquitin in the absence of extract. E3 selfubiquitination kinetics were characterized for each of the E3 ligases used in this screen, and each assay was optimized for its respective E3. The comparative rates of ubiquitin-E3 formation in our system are Nedd4 > MDM2 = XIAP > MuRF1 (Fig. 3a) . 
Inhibitors for MDM2 Ubiquitin Ligase Activity
Assay optimization for natural product extracts
The assay was modified to minimize the impact of nuisance compounds commonly encountered in natural product extracts such as sulfated polysaccharides and plant tannins, which can routinely inhibit cell-free assay systems. During optimization, a cross section of ~1500 organic and aqueous extracts from a variety of source organisms, as well as a specific sample set selected for observed interference in other assay systems, was used to test the robustness of the assay system. An initial test of the screen as used for pure compound library screening resulted in an unacceptably high rate of extracts showing more than 50% inhibition (~40%, Fig. 3b ). Several assay parameters were then examined to reduce this rate of positive response. To reduce problems associated with compound classes that nonspecifically bind to proteins, we added 0.05% BSA to the reaction mixture. To more specifically target E3 inhibitors, rather than compounds that inhibit E1 or E2, we further modified the assay so that E1 and E2 were preincubated in the absence of extract prior to the addition of MDM2 and extract to precharge the E2 and reduce its inhibition. Additional changes included prebinding MDM2 to the plate to eliminate nonspecific GST-glutathione interaction inhibitors and washing the plate prior to addition of the detection antibody to prevent extract-dependent inhibition of antibody binding and control the duration of E3 activity. These changes dramatically decreased the extent of inhibition by the test extracts, reducing strong inhibitors from 40% to <2% of the sample pool (Fig. 3b) , an acceptable level for a primary screening assay of natural product extracts. In preliminary work with 1586 extracts and in the screen of 143,874 natural product extracts, no significant interference was observed from commonly challenging sample components such as tannins, sulfated polysaccharides, or inherently fluorescent compounds in the optimized assay. The Z′ score, a measure of assay reproducibility comparing variability of average control values and average sample values within plates, 11 was 0.74 for this assay (Z ≥ 0.5 is the commonly accepted standard for a robust assay).
Results of the screen for inhibitors of MDM2 ubiquitin ligase activity
The primary screen encompassed 143,874 natural product extracts from the U.S. National Cancer Institute's Natural Products Repository. The extracts were classified by extraction solvent (aqueous or organic) and source (algae, microbial, marine invertebrate, or terrestrial plant). Data from the primary screen were grouped by solvent and source (ex. organic microbial) for analysis. Hits were defined as extracts demonstrating single-point MDM2 inhibition greater than the mean plus 3 standard deviations of all samples within their group. Inhibitory activity of the selected extracts was confirmed if multiple retests averaged within a single standard deviation of the initial value. Confirmed hits were further tested for inhibition of the HECT domain E3 Nedd 4, as well as the RF E3 ligases MuRF1 and XIAP. Of the 2834 hits initially identified, 2207 were confirmed as MDM2 inhibitors (78% confirmation, 1.5% overall hit rate). Of the confirmed hits, 472 did not inhibit Nedd 4 (thereafter considered RF selective), and 94 of the RF selective extracts were selective for MDM2 versus MuRF1 and XIAP ( Table 1) . From the 472 RF selective extracts originally identified, 104 were assayed in human RPE, a normal cell model, and RPE-E1A cells 12 (RPE cells transformed with adenovirus E1A), a cancer cell model, to determine their effect on several apoptotic biomarkers. Nutlin, an inhibitor of MDM2/p53 interaction, 16 was used as a control for this assay and demonstrated increases in cleaved caspase 3 and cleaved PARP levels in transformed versus nontransformed cells. This profile was used to define desirable responses for hit extracts; 47 extracts matched this profile, 19 of which (5 marine, 3 microbial, and 11 plant) were members of the MDM2 selective set. Active constituents from the extracts are currently being isolated and characterized.
The natural product sempervirine inhibits MDM2 autoubiquitination and MDM2-mediated p53 ubiquitination
In addition to the National Cancer Institute (NCI) repository extracts, 4048 previously purified natural products were screened in both the primary and secondary E3 assays. From this library, 31 compounds were defined as primary actives; 19 of these exhibited reproducible MDM2 inhibition, and 8 were RF selective. In a plate-based assay, 1 compound, sempervirine (Fig. 4a) , inhibited MDM2 auto-ubiquitination with an IC 50 of 8 μg/mL (Fig. 4b) . To examine the biological relevance of this activity, we employed RPE cells as a normal model. Incubation of cultured RPE cells with sempervirine led to dose-dependent increases in levels of p53 and MDM2 (Fig. 4c,d, respectively) . In normal systems, ubiquitin ladders can be detected above a protein of interest with bands corresponding to each ubiquitin addition (approximately 8.5 kDa each). The ubiquitin ladder above p53, seen with the proteosome inhibitor calpain inhibitor I (ALLN), was absent in cells treated with sempervirine ( Fig.  4c) . These data suggest that sempervirine inhibits p53 degradation at the point of ubiquitination, not a later step in the proteosomal pathway.
The cell-free inhibition of MDM2 auto-ubiquitination by sempervirine was confirmed in cells using p53/MDM2 null MEFs, which were transiently transfected with an MDM2 plasmid driven by a p53-independent cytomegalovirus (CMV) promoter. Sempervirine increased MDM2 levels in these cells in a dose-dependant manner (Fig. 4e) . The increased MDM2 levels were due solely to inhibition of MDM2 E3 ligase activity and not from p53 feedback inhibition, indicating that sempervirine inhibits MDM2 auto-ubiquitination and degradation in cells.
To further establish the results indicating that sempervirine blocks MDM2-mediated p53 degradation, we transiently cotransfected U20S cells with plasmids encoding p53 and MDM2. Treatment with ALLN resulted in inhibition of p53 degradation and accumulation of ubiquitinated p53 ladders (Fig. 5a) . Sempervirine treatment also inhibited p53 degradation, but p53 ladders were not seen (Fig. 5a) . To confirm that the lack of the ubiquitinated p53 ladder was an effect of sempervirine, we simultaneously treated cells with both sempervirine and ALLN. The ubiquitinated p53 ladder, seen in the ALLN DMSO control, is absent from all sempervirine-treated samples (Fig. 5b) , confirming that sempervirine prevents the ubiquitination of p53.
Finally, although sempervirine induced p53 accumulation, it was unknown at this point if the p53 was transcriptionally active. To determine if this was so, we used U20S cells stably transfected with a p53-responsive luciferase reporter (U20S-pG13) 15 to assess p53 transcriptional activity. The results show a dosedependant increase in luciferase expression with sempervirine treatment (Fig. 5c) , confirming that sempervirine-accumulated p53 is transcriptionally active. This increase was greater than that induced by general proteosome inhibitor ALLN (which results in the accumulation of ubiquitinated p53) but less than that induced by the DNA-damaging agent adriamycin.
Sempervirine preferentially induces cell death in p53 wt vs. p53 null and transformed vs. nontransformed cells
Next, we examined the effect of sempervirine on the viability of cells expressing or deficient in wild-type p53. MEFs, from wild type (C8) and p53-deficient (A9) mice, were transformed with adenovirus E1A protein and activated Ha-Ras. 17 We also investigated whether sempervirine-mediated cell death was selective for normal versus transformed cells using RPE and RPE-E1A cells. Viability was measured by Trypan blue exclusion after 20 h of sempervirine exposure. The results (Fig. 6 ) demonstrate that sempervirine increased cell death in C8 cells in a dosedependent manner, whereas A9 cells were relatively resistant to sempervirine, and sempervirine induced significant cell death in transformed RPE-E1A but not normal RPE cells. Together, these results indicate that sempervirine-mediated cell death is preferential to transformed cells and dependant on p53 activity. We expanded on these results with additional studies measuring the cleavage of caspase 3 and PARP. As shown in Figure 7a , increased caspase 3 and PARP cleavage was observed in plate-based ECL, and dose-dependant PARP cleavage was observed by Western blot after sempervirine exposure for RPE-E1A and RPE cells (Fig. 7b) .
Additional evidence of sempervirine's capacity to preferentially induce apoptosis in transformed versus normal cells was obtained by determining the percentage of nuclei with apoptosis-indicative sub-G1 DNA content by fluorescent-activated cell sorting (FACS) analysis. Increased numbers of nuclei with sub-G1 DNA content were observed in sempervirine-treated RPE-E1A but not RPE cells (data not shown).
DISCUSSION
More than half of the current clinically used chemotherapeutic agents are derived from natural products. 4 Despite this fact, most modern pharmaceutical HTS programs do not regularly screen natural product extracts due to inherent difficulties associated with these complex mixtures. Here we explored the utility of a new platform, solid-surface electrochemiluminescence, in screening natural product extracts for inhibitors of the ubiquitin ligase activity of MDM2. In contrast to previously reported assays that have screened for inhibitors of the p53-MDM2 interaction, [18] [19] [20] we have sought and identified inhibitors of the ubiquitin ligase activity of MDM2. A previous report from our group on screening pure compound libraries using a MDM2 catalytic assay system 21 identified general inhibitors that inhibited E1 and E2 as well as the E3 ligase MDM2. Here, Ub-E2 was used as a substrate-in-excess prior to combination with E3 and the test extract to selectively identify E3 inhibitors. In addition, the assay was made substantially more robust than that previously reported, thereby enabling the screening of complex extracts with success (see Fig. 2) . The utilization of a secondary screening strategy with the additional E3 ligase targets XIAP, MuRF1, and Nedd4 greatly aided in the prioritization of lead extracts and enhanced downstream efficiencies. One result of this novel screening strategy was the identification of the natural product sempervirine as an E3 inhibitor. This agent inhibited MDM2 ligase activity, leading to accumulation of nonubiquitinated p53 that retained activity as a transcriptional regulator in cells. As a result, sempervirine preferentially induces p53-mediated cell death in transformed cells while having little toxicity to normal cells. Sempervirine was first described in 1986 as a chemoprotective agent in mice inoculated with YC8 lymphoma or Ehrlich carcinoma cells. Administration of 0.15 mg/kg (Q12 h) sempervirine resulted in 80% survival rate for lymphoma and 50% survival rate for carcinoma. 22 The compound was also found to be synergistic with other chemotherapeutic agents such as cis-platinum. 22 The inhibitory effect of sempervirine against MDM2 E3 activity provides one explanation for the reported in vivo efficacy of this agent.
The clinically useful anticancer agent bortezomib acts by blocking the proteosome, preventing the degradation of proteins in general and leading to apoptosis in sensitive cells. The proteosomal degradation pathway encompasses many novel molecular targets that hold therapeutic potential for activity in a diverse array of cancers, including MDM2. Inhibitors of the MDM2/p53 binding interaction have been reported, including peptides, 20 protein epitope mimetics, 23 the nutlins, 16 and RITA (reactivation of p53 and induction of tumor cell apoptosis). 19 Some of these agents were shown to increase p53 levels in transformed cells and selectively induce apoptosis. E3 inhibitors represent another class of agent targeting a different aspect of this pro-apoptotic pathway. As reported here, MDM2 ubiquitin ligase inhibitors such as sempervirine can increase levels of p53 and stimulate apoptosis in transformed cells. Compounds derived from natural product extracts have repeatedly shown their value as drug leads 
